Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization

Executive Summary

Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.

You may also be interested in...



Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.

Ebola Vaccines: FDA Advisory Committee Convenes As Outbreak Recedes

Challenge of testing vaccines when infections seem to be coming under control is among potential issues for May 12 meeting.

Priority Review Vouchers Could Be Used Frequently Next Year

FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel